Literature DB >> 14722674

Influence of TSH on uptake of [18F]fluorodeoxyglucose in human thyroid cells in vitro.

J T Deichen1, C Schmidt, O Prante, S Maschauer, T Papadopoulos, T Kuwert.   

Abstract

Recent clinical evidence suggests that positron emission tomography with fluorine-18 fluorodeoxyglucose (FDG-PET) is more accurate in detecting thyroid carcinomatous tissue at high than at low TSH levels. The aim of this study was to determine the influence of TSH on FDG uptake in human thyroid cells in vitro. Monolayers of human thyroid tissue were cultured after mechanical disintegration and enzymatic digestion of samples from patients undergoing surgery for nodular goitre. The purity of thyroid cell preparations was ascertained by immunohistochemical staining for the epithelial antigen KL-1, and their viability by measuring the synthesis of thyroglobulin in vitro. The cells were incubated with 0.8-1.5 MBq FDG/ml uptake medium for 1 h. FDG uptake in thyroid cells was quantified as percent of whole FDG activity per well (% ID) or as % ID in relation to total protein mass. This experimental protocol was subsequently varied to study the effect of incubation time, glucose dependency and TSH. Furthermore, radio-thin layer chromatography was used to identify intracellular FDG metabolites. FDG accumulated in the thyroid cells linearly with time, doubling roughly every 20 min. Uptake was competitively inhibited by unlabelled glucose and decreased to approximately 70% at 100 mg/dl glucose compared to the value measured in glucose-free medium. FDG was intracellularly trapped as FDG-6 phosphate and FDG-1,6-diphosphate. TSH significantly increased FDG uptake in vitro in a time- and concentration-dependent manner: Cells cultured at a TSH concentration of 50 micro U/ ml doubled FDG uptake compared to TSH-free conditions, and uptake after 72 h of TSH pre-incubation was approximately 300% of that without TSH pre-incubation. TSH stimulates FDG uptake by benign thyroid cells in a time- and concentration-dependent manner. This supports the clinical evidence that in well-differentiated thyroid carcinomas, most of which are still TSH-sensitive, FDG-PET is more accurate at high levels of TSH.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14722674     DOI: 10.1007/s00259-003-1401-0

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  33 in total

1.  Should high hTg levels in the absence of iodine uptake be treated?

Authors:  M Biermann; O Schober
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-01       Impact factor: 9.236

Review 2.  The thyrotropin receptor and the regulation of thyrocyte function and growth.

Authors:  G Vassart; J E Dumont
Journal:  Endocr Rev       Date:  1992-08       Impact factor: 19.871

3.  Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer.

Authors:  M Dietlein; K Scheidhauer; E Voth; P Theissen; H Schicha
Journal:  Eur J Nucl Med       Date:  1997-11

Review 4.  Detection of residual and recurrent differentiated thyroid carcinoma by serum thyroglobulin measurement.

Authors:  C A Spencer; J S LoPresti; S Fatemi; J T Nicoloff
Journal:  Thyroid       Date:  1999-05       Impact factor: 6.568

5.  Influence of thyroid-stimulating hormone levels on uptake of FDG in recurrent and metastatic differentiated thyroid carcinoma.

Authors:  F Moog; R Linke; N Manthey; R Tiling; P Knesewitsch; K Tatsch; K Hahn
Journal:  J Nucl Med       Date:  2000-12       Impact factor: 10.057

6.  Follow-up regimen of differentiated thyroid carcinoma in thyroidectomized patients after thyroid hormone withdrawal.

Authors:  W J Oyen; C Verhagen; E Saris; W J van den Broek; G F Pieters; F H Corsten
Journal:  J Nucl Med       Date:  2000-04       Impact factor: 10.057

7.  Impact of cervical lymph node dissection on serum TG and the course of disease in TG-positive, radioactive iodine whole body scan-negative recurrent/persistent papillary thyroid cancer.

Authors:  A S Alzahrani; H Raef; A Sultan; S Al Sobhi; S Ingemansson; M Ahmed; A Al Mahfouz
Journal:  J Endocrinol Invest       Date:  2002-06       Impact factor: 4.256

8.  Uptake of [18F]fluorodeoxyglucose in human monocyte-macrophages in vitro.

Authors:  Jan Thiess Deichen; Olaf Prante; Michaela Gack; Kristin Schmiedehausen; Torsten Kuwert
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-11-05       Impact factor: 9.236

9.  18F-FDG-PET in the follow-up of thyroid cancer.

Authors:  P Lind; E Kresnik; Gerhild Kumnig; H-J Gallowitsch; Isabel Igerc; Sabine Matschnig; Iris Gomez
Journal:  Acta Med Austriaca       Date:  2003

10.  The mRNA levels of thyrotropin receptor, thyroglobulin and thyroid peroxidase in neoplastic human thyroid tissues.

Authors:  K Ohta; T Endo; T Onaya
Journal:  Biochem Biophys Res Commun       Date:  1991-02-14       Impact factor: 3.575

View more
  5 in total

Review 1.  Role of ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography in patients affected by differentiated thyroid carcinoma, high thyroglobulin level, and negative ¹³¹I scan: review of the literature.

Authors:  Francesco Bertagna; Giorgio Biasiotto; Emanuela Orlando; Giovanni Bosio; Raffaele Giubbini
Journal:  Jpn J Radiol       Date:  2010-11-27       Impact factor: 2.374

2.  Implication of 18F-fluorodeoxyglucose uptake by affected lymph nodes in cases with differentiated thyroid cancer.

Authors:  Takaaki Fujii; Reina Yajima; Hironori Tatsuki; Hiroyuki Kuwano
Journal:  Mol Clin Oncol       Date:  2016-07-12

Review 3.  Metabolic Reprogramming in Thyroid Carcinoma.

Authors:  Raquel Guimaraes Coelho; Rodrigo S Fortunato; Denise P Carvalho
Journal:  Front Oncol       Date:  2018-03-23       Impact factor: 6.244

Review 4.  Regulators of glucose uptake in thyroid cancer cell lines.

Authors:  Shabnam Heydarzadeh; Ali Asghar Moshtaghie; Maryam Daneshpoor; Mehdi Hedayati
Journal:  Cell Commun Signal       Date:  2020-06-03       Impact factor: 5.712

5.  Head-to-head comparison of F-18 FDG PET/CT in radioidine refractory thyroid cancer patients with elevated versus suppressed TSH levels a pilot study.

Authors:  Ludmila Santiago Almeida; Maidane Luisi Araújo; Allan Oliveira Santos; Lígia Vera Montali da Assumpção; Mariana Lopes Lima; Celso Darío Ramos; Denise Engelbrecht Zantut-Wittmann; Elba Cristina Etchebehere
Journal:  Heliyon       Date:  2020-03-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.